ACCESS BIOLOGICALS
Grifols Bio Supplies is the biological-materials division of Grifols, S.A., supplying human plasma proteins, blood cells, and serum to pharmaceutical manufacturers, IVD makers, cell therapy developers, and life science researchers from FDA- and EMA-licensed collection centers.
- Company typePublic
- Founded2006
- HeadquartersVista, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ACCESS BIOLOGICALS does
Grifols Bio Supplies — operating in the source data under the company label ACCESS BIOLOGICALS — is the biological-materials supply division of Grifols, S.A. (NYSE: GRFS), a publicly traded Spanish multinational healthcare company founded in Barcelona in 1909. Bio Supplies collects, processes, and distributes human-derived biological materials — including plasma-derived proteins (Human Serum Albumin, Immunoglobulins, Plasma Protein Fraction), blood cells (Whole Blood, Red Blood Cells, Buffy Coats, Leukopaks), and human plasma and serum (including Disease State plasma and serum, HumaCell Serum, Human Male AB Serum, Processed Human Plasma) — sourced from the parent group's network of more than 350 blood and plasma collection centers across the USA, Europe, and Africa. Materials are offered at multiple compliance tiers (EP/USP, GMP, RUO) from FDA- and EMA-licensed centers, with the Plasma Protein Fraction carrying an FDA therapeutic license.
The division serves four primary customer segments: pharmaceutical manufacturers using biological materials as excipients or raw inputs for drug manufacturing; in vitro diagnostics (IVD) manufacturers requiring plasma and serum for assay controls and calibrators; cell therapy companies (including CAR-T developers) sourcing Leukopaks and serum for cell-culture and starting materials; and life science researchers at academic, clinical, and biotech organizations. Differentiation rests on vertical integration into the parent company's plasma collection infrastructure, regulatory licensing across multiple jurisdictions, and breadth of compliance grades — capabilities the company describes as the world's largest plasma collection network.
Commercially, Bio Supplies operates a sales-led B2B motion. Customers engage via a "Request a Rep" inquiry form on biosuppliesproducts.com or through direct sales representatives; pricing is not publicly disclosed and is negotiated per engagement. The division supports go-to-market through content (website, educational brochures, blog), a LinkedIn presence, and participation in major industry events (Advanced Therapies Week, ISCT, CPHI, ADLM, AABB, MEDICA, Cell & Gene Therapy International). Revenue mechanics are transactional product sales of biological inputs rather than licensing or subscription; however, division-specific revenue is not separately disclosed by Grifols. Bio Supplies has no independent funding history as it is wholly owned within Grifols' corporate structure.
ACCESS BIOLOGICALS firmographics
Firmographics- Name
- ACCESS BIOLOGICALS
- Legal name
- Grifols Bio Supplies Inc
- Website
- https://accessbiologicals.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Grifols Bio Supplies is the biological-materials division of Grifols, S.A., supplying human plasma proteins, blood cells, and serum to pharmaceutical manufacturers, IVD makers, cell therapy developers, and life science researchers from FDA- and EMA-licensed collection centers.
- Ownership category
- akta.pro rank
ACCESS BIOLOGICALS industry classification
Industry- Product category
- Biological Materials Supply
- NAICS
- Blood and Organ Banks (621991), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines) (HLAGAGAI)
- akta.pro secondary industries
- Plasma-Derived & Blood Products Distributors (HLAIAJAJ), Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI), Plasma Fractionation & Purification Manufacturing (HLAIAHAI)
Keywords
Where ACCESS BIOLOGICALS is headquartered
LocationHeadquarters
- HQ city
- Vista
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
ACCESS BIOLOGICALS business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Biological materials sales: Sale of human-derived biological materials including plasma proteins, blood cells, and serum products to pharmaceutical and diagnostic manufacturers
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
ACCESS BIOLOGICALS product offering
Product offeringCore offering
Grifols Bio Supplies collects, processes, and distributes human-derived biological materials sourced from its own network of FDA- and EMA-licensed blood and plasma centers across the USA, Europe, and Africa. The product portfolio spans plasma-derived proteins (Human Serum Albumin EP/USP, Immunoglobulins EP/USP, Plasma Protein Fraction USP), blood cell components (Whole Blood, Red Blood Cells, Buffy Coats, Leukopaks), and human plasma and serum products (Human Serum, Human Plasma, Processed Human Plasma, Human Male AB Serum, HumaCell Serum, Disease State Plasma and Serum). Materials are offered in multiple compliance grades (EP/USP, GMP, RUO) tailored to pharmaceutical manufacturing, IVD manufacturing, cell therapy, and life science research applications.
Product overview
Grifols Bio Supplies operates as a division of Grifols, providing a comprehensive portfolio of human biological materials for pharmaceutical manufacturing, in vitro diagnostics (IVD) manufacturing, cell therapy, and life science research. Their product portfolio includes three main categories: (1) Proteins including Human Serum Albumin (EP/USP), Immunoglobulins (EP/USP), and Plasma Protein Fraction (USP); (2) Blood Cells including Whole Blood, Red Blood Cells, Buffy Coats, and Leukopaks; and (3) Human Plasma and Serum including Human Serum, Human Plasma, Processed Human Plasma, Human Male AB Serum, HumaCell Serum, and Disease State Plasma and Serum. Materials are collected from Grifols' own network of FDA- and EMA-licensed blood and plasma centers, with over 350 collection centers across the USA, Europe, and Africa. Products are available in different compliance levels including EP/USP, GMP, and RUO grades.
Differentiator
Problem solved
Functional benefit
Products and services
- Human Serum Albumin (EP/USP) Human plasma-derived albumin protein meeting European Pharmacopoeia and United States Pharmacopeia standards, used as an excipient in pharmaceutical manufacturing.
- Immunoglobulins (EP/USP) Plasma-derived immunoglobulin products compliant with EP and USP standards for pharmaceutical and diagnostic manufacturing applications.
- Plasma Protein Fraction (USP) Proprietary plasma protein fraction with a therapeutic license from the US FDA, used in pharmaceutical manufacturing.
- Whole Blood Human whole blood from standard blood donations, containing red blood cells, white blood cells, and platelets suspended in plasma.
- Red Blood Cells Red blood cells prepared from whole blood by removing plasma, used for research, development, and manufacturing needs.
- Buffy Coats Uncoagulated blood fraction containing most white blood cells and platelets after density gradient centrifugation, used in cell therapy and research applications.
- Leukopaks Blood-derived apheresis product rich in mononuclear leukocytes, useful for cell therapy as a sourcing material due to its high concentration of leukocytes. Available in fresh or cryopreserved formats from US and EU.
- Human Serum Human serum obtained from whole blood allowed to coagulate naturally without anticoagulants, collected at FDA- and EMA-licensed centers.
- Human Plasma Human plasma obtained via apheresis, a specialized technique that separates plasma from whole blood, safely returning red blood cells, white blood cells, and platelets to the donor.
- Processed Human Plasma Alternative to human serum for producing controls and calibrators, providing a cleaner matrix for accurate analyte measurement and improved assay reliability.
- Human Male AB Serum Blood-derived material collected from male individuals with AB blood type, suitable for various cell culture applications. Manufactured under cGMP.
- HumaCell Serum Human serum ideal for culturing human cells, sourced from mixed gender and mixed blood types. Manufactured under cGMP standards.
- Disease State Human Plasma and Serum Human plasma and serum characterized for the presence or absence of disease-specific biomarkers including autoimmune diseases, infectious diseases, inflammatory or other conditions.
Companies that use ACCESS BIOLOGICALS
Customer profileSegments4 records
Ideal customer profiles4 records
ACCESS BIOLOGICALS technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ACCESS BIOLOGICALS partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights5 records
ACCESS BIOLOGICALS competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
ACCESS BIOLOGICALS social profiles
Digital presenceACCESS BIOLOGICALS financial estimates
Financial estimateRevenue estimate
Valuation estimate
ACCESS BIOLOGICALS leadership team
Management profileNumber of profiles
ACCESS BIOLOGICALS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ACCESS BIOLOGICALS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ACCESS BIOLOGICALS
What does ACCESS BIOLOGICALS do?
Grifols Bio Supplies collects, processes, and distributes human-derived biological materials sourced from its own network of FDA- and EMA-licensed blood and plasma centers across the USA, Europe, and Africa. The product portfolio spans plasma-derived proteins (Human Serum Albumin EP/USP, Immunoglobulins EP/USP, Plasma Protein Fraction USP), blood cell components (Whole Blood, Red Blood Cells, Buffy Coats, Leukopaks), and human plasma and serum products (Human Serum, Human Plasma, Processed Human Plasma, Human Male AB Serum, HumaCell Serum, Disease State Plasma and Serum). Materials are offered in multiple compliance grades (EP/USP, GMP, RUO) tailored to pharmaceutical manufacturing, IVD manufacturing, cell therapy, and life science research applications.
Is ACCESS BIOLOGICALS a public or private company?
ACCESS BIOLOGICALS is a public company. It is classified as corporate owned and is currently operating.
When was ACCESS BIOLOGICALS founded?
ACCESS BIOLOGICALS was founded in 2006. It employs 11 to 50 people.
Where is ACCESS BIOLOGICALS based?
ACCESS BIOLOGICALS is headquartered in Vista, United States, in the North America region.
How does ACCESS BIOLOGICALS make money?
One revenue line is on record: biological materials sales.
Does ACCESS BIOLOGICALS have an API?
No public API is recorded for ACCESS BIOLOGICALS.
What industry is ACCESS BIOLOGICALS in?
ACCESS BIOLOGICALS's product category is Biological Materials Supply. Its primary akta.pro industry code is HLAGAGAI, Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines), with a secondary code of HLAIAJAJ, Plasma-Derived & Blood Products Distributors. Its NAICS code is 621991 and its SIC code is 2836.